Last reviewed · How we verify

NCT04459169: TEAM Red Flags

Cardiac Amyloidosis : Diagnostic Using Red Flag Signals

Status unknown Last updated 17 November 2020
What this trial tests

trial testing diagnostic algorithm in Cardiac Amyloidosis in 424 participants. Status unknown.

Timeline
30 September 2020
Primary endpoint
30 September 2021
31 December 2021

Quick facts

Lead sponsorUniversity Hospital Center of Martinique
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment424
Start date30 September 2020
Primary completion30 September 2021
Estimated completion31 December 2021
Sites3 locations across Martinique, Guadeloupe

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital Center of Martinique

Who can join

45 and older, any sex, with Cardiac Amyloidosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Cardiac amyloidosis is an increasingly contributor of degenerative cardiac diseases. However, its frequency remains underestimated, and diagnosis is often realized at late stages of the disease. A larger use of clinical and echographic Red Flag signals during routine echocardiographic examination may enhance the identification of early stage of the disease.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of diagnostic algorithm

Trials testing the same drug.

Other recruiting trials for Cardiac Amyloidosis

Currently open trials in the same condition.

Other University Hospital Center of Martinique trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04459169.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing